Piper Jaffray analyst JP Kim raised his price target on Insulet to $90 from $88 and kept his Overweight rating, citing the company's Q1 earnings beat and a conference call showcasing the management "oozing with confidence". Kim further notes that Insulet stands to benefit from the tailwinds in Animas, UNH and Medicare, along with a "flawless" execution by the management. The analyst adds that the tone of the call was even more bullish than the updated increase in guidance would suggest, which could result in another FY18 view upgrade after the release of Q2 results.